The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry
5.9.2024 15:00:00 CEST | Business Wire | Press release
The book is a must-read for transformation leaders looking to accelerate AI innovation and reduce time to value of their digital transformation programs
Cognite, the globally recognized authority in AI for industry, today announcedthe launch ofThe Cognite Atlas AI™Definitive Guide to Industrial Agents, a comprehensive manual for companies looking to accelerate the development and scale of AI solutions and reduce time to value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904796303/en/
The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry. (Photo: Business Wire)
The book explores advancements in AI over the past year and expands on industrial AI agents and the latest technological requirements necessary to make AI work for industry. The Cognite Atlas AI™ Definitive Guide to Industrial Agents offers real-world examples, practical advice, and tools digital leaders can use to implement AI agents that can improve decision-making processes and help their organizations achieve higher productivity, safety, and overall operational efficiency.
“According to a recent ARC Advisory Group Digital Transformation, Sustainability, and Technology survey, AI is the most impactful technology we'll see over the next five years,” said Janice Abel, ARC Advisory Group Principal Technology Analyst. “The Cognite Atlas AI™ Definitive Guide to Industrial Agents is a practical place to start for digital leaders looking to make AI work in complex industrial environments.”
“Cognite Atlas AI enables us to use AI to enhance decision-making and improve efficiency, like with an industrial agent fine-tuned to understand unstructured technical documentation and Aker BP’s equipment hierarchy," said Paula Doyle, Chief Digital Officer at Aker BP. "By implementing the Document Parser AI Agent, we are streamlining our equipment management process, saving thousands of hours of data-punching, and refocusing our experts on business problems that really matter to the short- and long-term success of our operation.”
“Data lakes and copilots are just the beginning. Industrial AI demands more than a one-size-fits-all approach,” said Paul Grenet, Chief Revenue Officer at Cognite. “Cognite Atlas AI unlocks the full potential of generative AI for industry with industrial agents that can accelerate efficiencies and generate tens of millions of dollars in business impact. These agents enable a new wave of intelligent, domain-specific applications that revolutionize how industries operate."
The Cognite Atlas AI™ Definitive Guide to Industrial Agents is the third installment of the Cognite Definitive Guide series, which also includes The Definitive Guide to Generative AI for Industryand The Definitive Guide to Industrial DataOps. The series demystifies industrial digitalization and helps make sense of the journey industrial companies must take to evaluate, adopt, and scale AI solutions across their organizations.
The full digital version of the book is available online for free. Physical copies are available by request. Visit Cognite.ai to learn more.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904796303/en/
Contacts
Michelle Holford
Michelle Holford
Vice President, Global PR, Cognite
Michelle.holford@cognite.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom